Company Overview and News

4
Permian Producers to Witness EPIC Solution for Bottlenecks

2018-10-19 zacks
Infrastructure bottlenecks in the Permian Basin, which stemmed from takeaway capacity constraints, is suffocating producers in the region for a long time now. Rising upstream activities in the region have outrun transportation capacity, which forced producers to sell their products at a discounted rate, trimming their profit levels. The extent of discount at the beginning of the year was $3.40 per barrel, which grew to $15.
ETP APA NBL MMP PAA FANG

1
FANG / Diamondback Energy, Inc. AMENDMENT NO. 2 TO FORM S-4

2018-10-18 sec.gov
Amendment No. 2 to Form S-4 Table of Contents As filed with the Securities and Exchange Commission on October 18, 2018 Registration No. 333-227328
FANG

4
MLP Monthly Report: September 2018

2018-10-15 seekingalpha
The September MLP Monthly Report can be found here offering insights on MLP industry news, the asset class’s performance, yields, valuations, and fundamental drivers.
KAAC APA SNSR AND LIT BFIT GXG SIL KRMA GXF CHII EV ACTX CHIE GOEX FINX CHIX SRET BOTZ CATH GURX GURI ALUM MILN CJHIQ URA BHI LNGR COPX QQQC GURU FANG

38
Is Laredo Petroleum A Buy At 52-Week Lows?

2018-10-13 seekingalpha
Laredo Petroleum is facing oil price related problems which will hurt its realizations that are forecasted to drop to 83% of WTI in Q3-2018 from well over 90% previously.
CHKVP PXD RDSB RDSA CHKDH CHKVZ CHKDG CHKDJ CHKDP CME RYDAF JAG CKRGZ RDS.B RDS.A CHKWZ 7018 CHK.WI CHK LPI RYDBF TRI OXY FANG

2
FANG / Diamondback Energy, Inc. AMENDMENT NO. 1 TO FORM S-4

2018-10-11 sec.gov - 1
Amendment No. 1 to Form S-4 Table of Contents As filed with the Securities and Exchange Commission on October 10, 2018 Registration No. 333-227328
FANG

1
FANG / Diamondback Energy, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G (Passive Investment)

2018-10-10 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8 )* Diamondback Energy, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 25278X109 (CUSIP Number)
FANG

1
FANG / Diamondback Energy, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G (Passive Investment)

2018-10-10 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8 )* Diamondback Energy, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 25278X109 (CUSIP Number)
FANG

57
E&P 'Middle Of The Road Club' (Permian Edition) #18-1

2018-10-08 seekingalpha - 5
E&P companies that are neither top institutional favorites nor companies I would classify in my Bottom of the Barrel Club may have wide appeal to investors.
GIS XOM PXD QEP AR CRZO WMB XOG NBL WLL PDCE SRCI SM CTLR NFX RRS WPX ESTE RGRLF RRC WTI CLR OXY AEUA HAL APC APA WPXP DVN CXO PE RRL COP ROSEU RSPP REI AMR EGN JAG ROSE CDEV D COG EOG RGRYY HP CVX LPI HK FANG

3
U.S. Oil And Gas M&A Soar 250% In Q3 To Highest Since 2012

2018-10-05 oilprice
Tsvetana is a writer for the U.S.-based Divergente LLC consulting firm with over a decade of experience writing for news outlets such as iNVEZZ and…
RSPP CXO FANG

3
Permian Producers Have A Power Problem

2018-10-03 oilprice
Tsvetana is a writer for the U.S.-based Divergente LLC consulting firm with over a decade of experience writing for news outlets such as iNVEZZ and…
NBL FANG

12
Covia Is Beginning To Divide And Conquer The Frac Sand Industry

2018-10-02 seekingalpha - 4
Covia is bifurcating the North American frac sand market, and whatever volumes are lost due to idling of facilities are more than offset by new local brown volumes.
CVIA FANG

29
E&P 'Middle Of The Road Club' (Non-Permian Edition) #18-1

2018-10-01 seekingalpha - 2
E&P companies that are neither top institutional favorites nor companies I would classify in my Bottom of the Barrel Club may have wide appeal to investors.
APC APA WPXP DVN QEP PE CXO EPE RRL AR CRZO ROSEU REI GPOR JNEEP AMR MUR.WI MUR JAG ROSE XOG JGPK NBL WLL PDCE SRCI SM CTLR COG BCEI NFX RRS JONE WPX RGRLF EOG RRC OAS RGRYY LPI MRO CLR ROAN AEUA FANG

9
Legacy Reserves: What Downside Realistically Is

2018-09-29 seekingalpha
A sky-high valuation assessment of Legacy Reserves by Baines Creek Capital shocked some investors last week, but those numbers don't look too unreasonable fundamentally.
LGCYP LGCYO LGCY EGN FANG

2
XOP Shares Are Rallying And Aren't Done Yet

2018-09-27 seekingalpha
Many E&Ps within XOP are displaying strong fundamentals, and are even growing production in bottlenecked environments.
SN DVN SCAZP XOP SNZYP FANG EOG

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 25278X109